EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sustained Delivery of the HIF1α Inhibitor Acriflavine via Polyurethane Nanocapsules Enables Long-Term Suppression of Choroidal Neovascularization

Narendra Pandala, Lorena De Melo Haefeli, Adnan Khan, Shradha Darira, Adam Goeken, Hailey Steffan, Jake Miller, Edwin M. Stone, Ian C. Han, Erin B. Lavik, Robert F. Mullins, Budd A. Tucker

ACS Nano Medicine · 16.11.2026

DOI: 10.1021/acsnanomed.6c00265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano Medicine, online erschienen am 16.11.2026. Verfasst von Narendra Pandala und 11 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Health and Human Services.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leaky choroidal neovascular membranes (CNVM), which form beneath the retina in patients with age-related macular degeneration (AMD), are a significant cause of irreversible vision loss. While antivascular endothelial growth factor (VEGF) therapies designed to prevent abnormal blood vessel growth and CNVM formation are effective for many patients, these drugs require repeat administration and have been associated with increased retinal atrophy. To address these shortcomings, in this study, we present a polyurethane nanocapsule formulation designed to provide sustained delivery of acriflavine, a small molecule inhibitor of HIF1α. The developed acriflavine nanocapsules were approximately 229 ± 42 nm in diameter and contained 49 ± 3 μg of drug per mg. In vitro delivery inhibited growth and proliferation of human endothelial cells without inducing cytotoxicity. At 2 weeks following intravitreal administration, significantly reduced CNVM size was detected in acriflavine nanocapsule-treated laser injury rats as compared to drug-free controls. In a follow-up extended time course study, we found that unlike free drug, a single intravitreal injection of acriflavine nanocapsules reduced CNVM incidence and size for a minimum of three months following administration. Ocular route of delivery analysis revealed that intravitreal injection of acriflavine nanocapsules was superior to subretinal and suprachoroidal delivery for reducing CNVM area without causing significant damage to the neural retina. Collectively, these findings demonstrate that intravitreal injection of acriflavine nanocapsules may be an effective therapeutic alternative to current anti-VEGF therapies for long-term suppression of pathologic neovascularization.

Förderung

  • U.S. Department of Health and Human Services

Zitieren

APA

Pandala, N., Haefeli, L. D. M., Khan, A., Darira, S., Goeken, A., Steffan, H., Miller, J., Stone, E. M., Han, I. C., Lavik, E. B., Mullins, R. F., & Tucker, B. A. (2026). Sustained Delivery of the HIF1α Inhibitor Acriflavine via Polyurethane Nanocapsules Enables Long-Term Suppression of Choroidal Neovascularization. ACS Nano Medicine. https://doi.org/10.1021/acsnanomed.6c00265

Vancouver

Pandala N, Haefeli LDM, Khan A, Darira S, Goeken A, Steffan H, et al. Sustained Delivery of the HIF1α Inhibitor Acriflavine via Polyurethane Nanocapsules Enables Long-Term Suppression of Choroidal Neovascularization. ACS Nano Medicine. 2026. doi:10.1021/acsnanomed.6c00265

BibTeX
@article{Pandala2026,
  author = {Pandala, Narendra and Haefeli, Lorena De Melo and Khan, Adnan and Darira, Shradha and Goeken, Adam and Steffan, Hailey and Miller, Jake and Stone, Edwin M. and Han, Ian C. and Lavik, Erin B. and Mullins, Robert F. and Tucker, Budd A.},
  title = {Sustained Delivery of the HIF1α Inhibitor Acriflavine via Polyurethane Nanocapsules Enables Long-Term Suppression of Choroidal Neovascularization},
  journal = {ACS Nano Medicine},
  year = {2026},
  doi = {10.1021/acsnanomed.6c00265}
}
Kostenlos starten →